RU2396261C2 - Производные хиназолинона, полезные в качестве ванилоидных антагонистов - Google Patents
Производные хиназолинона, полезные в качестве ванилоидных антагонистов Download PDFInfo
- Publication number
- RU2396261C2 RU2396261C2 RU2006146632/04A RU2006146632A RU2396261C2 RU 2396261 C2 RU2396261 C2 RU 2396261C2 RU 2006146632/04 A RU2006146632/04 A RU 2006146632/04A RU 2006146632 A RU2006146632 A RU 2006146632A RU 2396261 C2 RU2396261 C2 RU 2396261C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound according
- alkoxy
- treatment
- pain
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 9
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 208000002193 Pain Diseases 0.000 claims abstract description 25
- 125000005913 (C3-C6) cycloalkyl group Chemical class 0.000 claims abstract description 23
- 230000036407 pain Effects 0.000 claims abstract description 21
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- -1 C1-C6alkoxy Chemical class 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 13
- 150000002367 halogens Chemical class 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 125000004093 cyano group Chemical class *C#N 0.000 claims abstract description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 7
- 230000004913 activation Effects 0.000 claims abstract description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 108010062740 TRPV Cation Channels Proteins 0.000 claims description 10
- 102000011040 TRPV Cation Channels Human genes 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 3
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 229940125684 antimigraine agent Drugs 0.000 claims description 2
- 229940005483 opioid analgesics Drugs 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 239000003890 substance P antagonist Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 abstract description 4
- 102000005962 receptors Human genes 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- 239000002253 acid Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 230000014759 maintenance of location Effects 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 208000006673 asthma Diseases 0.000 description 14
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000005932 reductive alkylation reaction Methods 0.000 description 7
- 208000023504 respiratory system disease Diseases 0.000 description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 229960002504 capsaicin Drugs 0.000 description 6
- 235000017663 capsaicin Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 230000026030 halogenation Effects 0.000 description 5
- 238000005658 halogenation reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 108010025083 TRPV1 receptor Proteins 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 206010035653 pneumoconiosis Diseases 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000033116 Asbestos intoxication Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 208000007596 Byssinosis Diseases 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 229940122629 Vanilloid antagonist Drugs 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000028462 aluminosis Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 208000010123 anthracosis Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003441 asbestosis Diseases 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 208000004003 siderosis Diseases 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- OJVMSICJWQFIOS-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-hydroxy-2-propan-2-ylquinazolin-4-one Chemical compound CC(C)C1=NC2=CC(O)=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 OJVMSICJWQFIOS-UHFFFAOYSA-N 0.000 description 1
- ZXVGFOYXFWKWAV-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-nitro-2-propan-2-ylquinazolin-4-one Chemical compound CC(C)C1=NC2=CC([N+]([O-])=O)=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 ZXVGFOYXFWKWAV-UHFFFAOYSA-N 0.000 description 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical class CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- XBLNKLVBZMWWLK-UHFFFAOYSA-N 7-amino-3-(4-chlorophenyl)-2-propan-2-ylquinazolin-4-one Chemical compound CC(C)C1=NC2=CC(N)=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 XBLNKLVBZMWWLK-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- USFFYHXYHQGNDP-UHFFFAOYSA-N CC(C)C(N1c(cc2)ccc2C#N)=Nc(c(CO)c(cc2)O)c2C1=O Chemical compound CC(C)C(N1c(cc2)ccc2C#N)=Nc(c(CO)c(cc2)O)c2C1=O USFFYHXYHQGNDP-UHFFFAOYSA-N 0.000 description 1
- NRLBHPLWMGCODT-UHFFFAOYSA-N CC(C)C(N1c(cc2)ccc2C#N)=Nc(c(OC)c(cc2)O)c2C1=O Chemical compound CC(C)C(N1c(cc2)ccc2C#N)=Nc(c(OC)c(cc2)O)c2C1=O NRLBHPLWMGCODT-UHFFFAOYSA-N 0.000 description 1
- JFPXRFIBKKSHGY-UHFFFAOYSA-N CC(C)C(N1c(cc2)ccc2C#N)=Nc(cc(cc2)O)c2C1=O Chemical compound CC(C)C(N1c(cc2)ccc2C#N)=Nc(cc(cc2)O)c2C1=O JFPXRFIBKKSHGY-UHFFFAOYSA-N 0.000 description 1
- LQHCCKRDNPWMDV-UHFFFAOYSA-N CC(C)C(N1c(cc2)ccc2Cl)=Nc(c(-c2ccccc2)c(cc2)N)c2C1=O Chemical compound CC(C)C(N1c(cc2)ccc2Cl)=Nc(c(-c2ccccc2)c(cc2)N)c2C1=O LQHCCKRDNPWMDV-UHFFFAOYSA-N 0.000 description 1
- ZSUNZNJCQDWKKO-UHFFFAOYSA-N CC(C)C(N1c(cc2)ccc2Cl)=Nc(c(I)c(cc2)O)c2C1=O Chemical compound CC(C)C(N1c(cc2)ccc2Cl)=Nc(c(I)c(cc2)O)c2C1=O ZSUNZNJCQDWKKO-UHFFFAOYSA-N 0.000 description 1
- QIDPEWLCJJBSHW-UHFFFAOYSA-N CC(C)C(N1c2ccc(C)cc2)=Nc(cc(cc2)O)c2C1=O Chemical compound CC(C)C(N1c2ccc(C)cc2)=Nc(cc(cc2)O)c2C1=O QIDPEWLCJJBSHW-UHFFFAOYSA-N 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010052443 Myofascitis Diseases 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101100208026 Rattus norvegicus Trpv1 gene Proteins 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 206010062225 Urinary tract pain Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940025141 anafranil Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 208000014055 occupational lung disease Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055692 pamelor Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940118176 surmontil Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229940035276 tofranil-pm Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 229940045977 vivactil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Cereal-Derived Products (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0412769.2A GB0412769D0 (en) | 2004-06-08 | 2004-06-08 | Organic compounds |
| GB0412769.2 | 2004-06-08 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010112450/04A Division RU2449995C2 (ru) | 2004-06-08 | 2005-06-08 | Производные хиназолинона, полезные в качестве ванилоидных антагонистов |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006146632A RU2006146632A (ru) | 2008-07-20 |
| RU2396261C2 true RU2396261C2 (ru) | 2010-08-10 |
Family
ID=32696854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006146632/04A RU2396261C2 (ru) | 2004-06-08 | 2005-06-08 | Производные хиназолинона, полезные в качестве ванилоидных антагонистов |
| RU2010112450/04A RU2449995C2 (ru) | 2004-06-08 | 2005-06-08 | Производные хиназолинона, полезные в качестве ванилоидных антагонистов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010112450/04A RU2449995C2 (ru) | 2004-06-08 | 2005-06-08 | Производные хиназолинона, полезные в качестве ванилоидных антагонистов |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US7960399B2 (enExample) |
| EP (1) | EP1755606B2 (enExample) |
| JP (2) | JP4703650B2 (enExample) |
| KR (2) | KR20100101017A (enExample) |
| CN (1) | CN1956721B (enExample) |
| AT (1) | ATE376833T1 (enExample) |
| AU (2) | AU2005251476C1 (enExample) |
| BR (1) | BRPI0511933B8 (enExample) |
| CA (1) | CA2567821C (enExample) |
| CY (1) | CY1107846T1 (enExample) |
| DE (1) | DE602005003128T3 (enExample) |
| DK (1) | DK1755606T4 (enExample) |
| EC (2) | ECSP067067A (enExample) |
| ES (1) | ES2293584T5 (enExample) |
| GB (1) | GB0412769D0 (enExample) |
| HR (1) | HRP20070577T4 (enExample) |
| IL (1) | IL179532A (enExample) |
| MA (1) | MA28685B1 (enExample) |
| MX (1) | MXPA06014249A (enExample) |
| NO (1) | NO338181B1 (enExample) |
| NZ (1) | NZ551630A (enExample) |
| PL (1) | PL1755606T5 (enExample) |
| PT (1) | PT1755606E (enExample) |
| RU (2) | RU2396261C2 (enExample) |
| SG (1) | SG153811A1 (enExample) |
| SI (1) | SI1755606T2 (enExample) |
| TN (1) | TNSN06405A1 (enExample) |
| WO (1) | WO2005120510A1 (enExample) |
| ZA (1) | ZA200609634B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021235983A1 (ru) | 2020-05-20 | 2021-11-25 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б.Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия |
| RU2853589C2 (ru) * | 2019-02-15 | 2025-12-24 | Бауш +Ломб Айэленд Лимитед | Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2008024438A2 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
| AU2007325940A1 (en) * | 2006-11-06 | 2008-06-05 | Neurogen Corporation | Cis-cyclohexyl substituted pyrimidinone derivatives |
| CN101754774B (zh) | 2007-07-18 | 2013-08-21 | 诺瓦提斯公司 | Vr-1拮抗剂和cox-2抑制剂的协同组合 |
| US8915362B2 (en) | 2008-10-08 | 2014-12-23 | Ultimed, Inc. | Sharps container |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| WO2014138302A1 (en) * | 2013-03-05 | 2014-09-12 | University Of Notre Dame | Quinazolinone antibiotics |
| US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| US12600702B2 (en) | 2019-02-15 | 2026-04-14 | Bausch + Lomb Ireland Limited | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof |
| EP3923909A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | Methods for treating ocular surface pain |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CN116419918A (zh) * | 2020-08-06 | 2023-07-11 | 诺华股份有限公司 | 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品 |
| CN116456986A (zh) * | 2020-11-17 | 2023-07-18 | 苏州晶云药物科技股份有限公司 | 一种喹唑啉酮衍生物的新晶型及其制备方法 |
| UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
| IL319539A (en) | 2022-09-21 | 2025-05-01 | Bausch & Lomb Ireland Ltd | Crystalline polymorphic forms of TRPV1 antagonist and formulations thereof |
| KR20250030194A (ko) | 2023-08-24 | 2025-03-05 | 코웨이 주식회사 | 출수 장치 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0116268A1 (en) * | 1983-01-13 | 1984-08-22 | Tanabe Seiyaku Co., Ltd. | Novel quinazolinone derivative, a process for preparing the same and a pharmaceutical composition |
| EP0497150A1 (en) * | 1991-01-30 | 1992-08-05 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted quinazolones |
| RU96117801A (ru) * | 1996-09-06 | 1999-01-10 | С.Н. Дугин | Способ получения замещенных 4-хиназолинонов |
| US5869665A (en) * | 1994-08-08 | 1999-02-09 | Warner-Lambert Company | Quinazolinone derivatives as cholecystokinin (CCK) ligands |
| RU2164224C2 (ru) * | 1995-03-14 | 2001-03-20 | Новартис Аг | Трехзамещенные фенильные производные и фармацевтическая композиция |
| WO2003059355A1 (en) * | 2001-12-31 | 2003-07-24 | Hadasit Medical Research Services And Development Ltd. | Quinazolinone compounds in combined modalities for improved cancer treatment |
| US20030158198A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US82365A (en) * | 1868-09-22 | thompson | ||
| US220227A (en) * | 1879-10-07 | Improvement in stri klng-movements for clocks | ||
| US95650A (en) * | 1869-10-12 | Improvement in machines for bending sheet-metal for cornices | ||
| US49728A (en) * | 1865-09-05 | Improvement | ||
| DE239090C (enExample) | 1906-11-01 | |||
| US2749344A (en) | 1953-01-02 | 1956-06-05 | Burroughs Wellcome Co | Pyrimidine compounds |
| DE1224316B (de) | 1961-03-18 | 1966-09-08 | Beiersdorf & Co Ag P | Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen |
| US3515787A (en) * | 1962-06-27 | 1970-06-02 | Squibb & Sons Inc | Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones |
| DE1232152B (de) † | 1962-06-27 | 1967-01-12 | Heyden Chem Fab | Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten |
| GB1003802A (en) | 1963-06-04 | 1965-09-08 | Searle & Co | Pyrimidinone derivatives |
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| US3317388A (en) | 1964-11-20 | 1967-05-02 | Wallace & Tiernan Inc | Methods for treating pain |
| US3864362A (en) | 1970-05-27 | 1975-02-04 | Chinoin Gyogyszer Es Vegyeszet | Iso flavones |
| BE793594A (fr) | 1972-01-03 | 1973-07-02 | Pfizer | Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants |
| GB1495305A (en) | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 3-phenyl-4-oxo-4h-benzopyran derivatives |
| US4501755A (en) | 1981-05-01 | 1985-02-26 | Pennwalt Corporation | Isoflavones useful as anti-inflammatory agents |
| SU1262927A1 (ru) | 1985-01-09 | 1997-11-20 | Институт физико-органической химии и углехимии АН УССР | Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина |
| JPS62201882A (ja) | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
| JPS62193605A (ja) | 1986-02-20 | 1987-08-25 | Toray Ind Inc | 半透性複合膜の製造方法 |
| ZA873745B (en) | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
| WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| US5284853A (en) | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| EP0635263A3 (en) | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
| HUT68558A (en) | 1993-07-20 | 1995-06-28 | Chinoin Gyogyszer Es Vegyeszet | Method for preparing isoflavon derivatives |
| JPH09510695A (ja) | 1994-01-03 | 1997-10-28 | エイシア・ファーマシュウティカルズ，インコーポレイテッド | ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類およびそのグリシン／ｎｍｄａリセプターに対するアンタゴニストとしての使用 |
| JPH07258224A (ja) | 1994-03-24 | 1995-10-09 | Dai Ichi Seiyaku Co Ltd | 二環性化合物 |
| US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
| WO1997044041A1 (en) | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| IT1289154B1 (it) | 1997-01-03 | 1998-09-29 | Chiesi Farma Spa | Derivati di isoflavone loro preparazione e loro impiego terapeutico |
| JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
| US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| DE69819345T2 (de) | 1997-08-20 | 2004-07-15 | The Regents Of The University Of California, Oakland | Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung |
| WO1999037675A1 (en) | 1998-01-22 | 1999-07-29 | The Regents Of The University Of California | Nucleic acid sequences encoding capsaicin receptors |
| PL343007A1 (en) | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| WO2000050387A1 (en) * | 1999-02-22 | 2000-08-31 | Pacific Corporation | Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof |
| GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
| AU4742101A (en) | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO2002008221A2 (en) | 2000-07-20 | 2002-01-31 | Neurogen Corporation | Capsaicin receptor ligands |
| WO2002016318A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| FR2815033B1 (fr) | 2000-10-06 | 2003-09-05 | Negma Lab | Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| EP1377576A2 (en) | 2001-03-26 | 2004-01-07 | Novartis AG | Pyridine derivatives |
| CA2455754A1 (en) | 2001-07-31 | 2003-02-20 | Bayer Healthcare Ag | Amine derivatives |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| US7381730B2 (en) | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
| AU2003238157A1 (en) * | 2002-06-18 | 2003-12-31 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| EP1560816A1 (en) | 2002-07-05 | 2005-08-10 | F. Hoffmann-La Roche Ag | Quinazoline derivatives |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| US20060052345A1 (en) | 2002-11-04 | 2006-03-09 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
| SI1611112T1 (sl) | 2003-02-11 | 2012-12-31 | Vernalis (R&D) Limited | Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov |
| JPWO2004078719A1 (ja) | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−４（３ｈ）−オン化合物 |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| CA2545725A1 (en) † | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| UA83416C2 (en) | 2004-02-13 | 2008-07-10 | Баниу Фармасьютикал Ко., Лтд. | Fused ring 4-oxopyrimidine derivative |
| GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| US20090298856A1 (en) | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| CN101754774B (zh) | 2007-07-18 | 2013-08-21 | 诺瓦提斯公司 | Vr-1拮抗剂和cox-2抑制剂的协同组合 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
-
2004
- 2004-06-08 GB GBGB0412769.2A patent/GB0412769D0/en not_active Ceased
-
2005
- 2005-06-08 SG SG200903909-0A patent/SG153811A1/en unknown
- 2005-06-08 KR KR1020107019024A patent/KR20100101017A/ko not_active Ceased
- 2005-06-08 US US11/569,802 patent/US7960399B2/en not_active Expired - Lifetime
- 2005-06-08 MX MXPA06014249A patent/MXPA06014249A/es active IP Right Grant
- 2005-06-08 AU AU2005251476A patent/AU2005251476C1/en not_active Expired
- 2005-06-08 SI SI200530141T patent/SI1755606T2/sl unknown
- 2005-06-08 CA CA2567821A patent/CA2567821C/en not_active Expired - Lifetime
- 2005-06-08 DK DK05750584.4T patent/DK1755606T4/da active
- 2005-06-08 HR HR20070577T patent/HRP20070577T4/hr unknown
- 2005-06-08 EP EP05750584A patent/EP1755606B2/en not_active Expired - Lifetime
- 2005-06-08 WO PCT/EP2005/006253 patent/WO2005120510A1/en not_active Ceased
- 2005-06-08 BR BRPI0511933A patent/BRPI0511933B8/pt not_active IP Right Cessation
- 2005-06-08 RU RU2006146632/04A patent/RU2396261C2/ru active
- 2005-06-08 CN CN200580016187.3A patent/CN1956721B/zh not_active Expired - Lifetime
- 2005-06-08 NZ NZ551630A patent/NZ551630A/en not_active IP Right Cessation
- 2005-06-08 ES ES05750584T patent/ES2293584T5/es not_active Expired - Lifetime
- 2005-06-08 PL PL05750584T patent/PL1755606T5/pl unknown
- 2005-06-08 DE DE602005003128T patent/DE602005003128T3/de not_active Expired - Lifetime
- 2005-06-08 PT PT05750584T patent/PT1755606E/pt unknown
- 2005-06-08 JP JP2007526311A patent/JP4703650B2/ja not_active Expired - Lifetime
- 2005-06-08 RU RU2010112450/04A patent/RU2449995C2/ru active
- 2005-06-08 KR KR1020067025788A patent/KR101018607B1/ko not_active Expired - Lifetime
- 2005-06-08 AT AT05750584T patent/ATE376833T1/de active
-
2006
- 2006-11-20 ZA ZA200609634A patent/ZA200609634B/xx unknown
- 2006-11-23 IL IL179532A patent/IL179532A/en active IP Right Grant
- 2006-12-07 TN TNP2006000405A patent/TNSN06405A1/en unknown
- 2006-12-07 EC EC2006007067A patent/ECSP067067A/es unknown
- 2006-12-28 MA MA29565A patent/MA28685B1/fr unknown
-
2007
- 2007-01-08 NO NO20070122A patent/NO338181B1/no unknown
-
2008
- 2008-01-03 CY CY20081100014T patent/CY1107846T1/el unknown
-
2009
- 2009-11-06 AU AU2009233684A patent/AU2009233684A1/en not_active Abandoned
-
2011
- 2011-01-21 JP JP2011010997A patent/JP5400812B2/ja not_active Expired - Lifetime
- 2011-04-19 US US13/089,943 patent/US8211902B2/en not_active Expired - Lifetime
-
2012
- 2012-02-14 EC ECSP12007067 patent/ECSP12007067A/es unknown
- 2012-03-29 US US13/434,248 patent/US8809528B2/en not_active Expired - Lifetime
-
2014
- 2014-07-02 US US14/322,165 patent/US9102653B2/en not_active Expired - Lifetime
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0116268A1 (en) * | 1983-01-13 | 1984-08-22 | Tanabe Seiyaku Co., Ltd. | Novel quinazolinone derivative, a process for preparing the same and a pharmaceutical composition |
| EP0497150A1 (en) * | 1991-01-30 | 1992-08-05 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted quinazolones |
| US5869665A (en) * | 1994-08-08 | 1999-02-09 | Warner-Lambert Company | Quinazolinone derivatives as cholecystokinin (CCK) ligands |
| RU2164224C2 (ru) * | 1995-03-14 | 2001-03-20 | Новартис Аг | Трехзамещенные фенильные производные и фармацевтическая композиция |
| RU96117801A (ru) * | 1996-09-06 | 1999-01-10 | С.Н. Дугин | Способ получения замещенных 4-хиназолинонов |
| WO2003059355A1 (en) * | 2001-12-31 | 2003-07-24 | Hadasit Medical Research Services And Development Ltd. | Quinazolinone compounds in combined modalities for improved cancer treatment |
| US20030158198A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2853589C2 (ru) * | 2019-02-15 | 2025-12-24 | Бауш +Ломб Айэленд Лимитед | Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила |
| WO2021235983A1 (ru) | 2020-05-20 | 2021-11-25 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б.Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2449995C2 (ru) | Производные хиназолинона, полезные в качестве ванилоидных антагонистов | |
| US8552015B2 (en) | Quinazolinone derivatives and their use as CB agonists | |
| US20080293939A1 (en) | Quinazolinone derivatives useful as anti-hyperalgesic agents | |
| CZ304061B6 (cs) | Derivát chinazolinu, farmaceutická kompozice a lécivo s jeho obsahem | |
| SK284108B6 (sk) | 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom | |
| US6956039B2 (en) | Nitrogenous heterocylic compounds | |
| US20040259881A1 (en) | Nitrogenous heterocyclic compounds | |
| HK1105577B (en) | Quinazolinone derivatives useful as vanilloid antagonists | |
| HK1105577C (en) | Quinazolinone derivatives useful as vanilloid antagonists |